IGKV1D-22 and acute kidney injury: Small‐molecule inhibitors targeting the S100a8/a9‐Tlr4‐Nfκb signaling pathway suppress kidney inflammation, alleviate tissue damage, protect kidney function, and decrease mortality in AKI.